( June 8, 2026, 1:18 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on June 5 affirmed an Illinois federal judge’s finding that an appellant biopharmaceutical company’s generic version of an injectable antibiotic treatment method infringes another company’s patents. The panel also rejected the appellant company’s argument that the patents were invalid for lack of adequate written description (Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc., Nos. 25-1281, 25-1282, Fed. Cir., 2026 U.S. App. LEXIS 16259)....